Cleared Traditional

K142033 - VERIGENE ENTERIC PATHOGEN NUCLEIC ACID ...

K142033 is the FDA 510(k) clearance for VERIGENE ENTERIC PATHOGEN NUCLEIC ACID ... by Nanospere,Inc.. It is a Class 2 Microbiology device (product code PCH) cleared through the Traditional 510(k) pathway after a 77-day FDA review.

K142033 · Nanospere,Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2014
Decision
77d
Days
Class 2
Risk

K142033 is an FDA 510(k) clearance for the VERIGENE ENTERIC PATHOGEN NUCLEIC ACID TEST (EP). Classified as Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-based Assay System (product code PCH), Class II - Special Controls.

Submitted by Nanospere,Inc. (Northbrook, US). The FDA issued a Cleared decision on October 10, 2014 after a review of 77 days - a notably fast clearance cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3990 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Nanospere,Inc. devices

Submission Details

510(k) Number K142033 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 25, 2014
Decision Date October 10, 2014
Days to Decision 77 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
25d faster than avg
Panel avg: 102d · This submission: 77d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code PCH Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-based Assay System
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3990
Definition A Gastrointestinal Pathogen Panel Multiplex Nucleic Acid Assay Is A Qualitative In Vitro Diagnostic Device Intended To Simultaneously Detect And Identify Multiple Gastrointestinal Microbial Nucleic Acids Extracted From Human Stool Specimens. The Detection And Identification Of A Specific Gastrointestinal Microbial Nucleic Acid From Individuals Exhibiting Signs And/or Symptoms Of Gastrointestinal Infection Aids In The Diagnosis Of Gastrointestinal Infection When Used In Conjunction With Clinical Evaluation And Other Laboratory Findings.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - PCH Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-based Assay System

All 27
Devices cleared under the same product code (PCH) and FDA review panel - the closest regulatory comparables to K142033.
BD MAX Extended Enteric Bacterial Panel, BD MAX System
K170308 · Becton, Dickinson and Company · May 2017
BD MAX Enteric Parasite Panel, BD MAX Instrument
K143648 · Becton, Dickinson and Company · Aug 2015
Xpert Norovirus, GeneXpert Dx Systems (GX-I, GX-11, GX-IV, GX-XVI), GeneXpert Infinity-48 System, GeneXpert Infinity-48s System, GeneXpert Infinity-80 System
K142501 · Cepheid · Nov 2014